MeSH tree: D12.776.124.486.485.114.224.060
Researchers at the University of Oulu have made a discovery in breast cancer research. They demonstrated that the extracellular matrix protein collagen XVIII significantly promotes breast cancer progression and metastasis. ...
Oct 17, 2023
0
49
Researchers at Duke University School of Medicine, studying multiple sclerosis (MS) in mice, identified a protein that could reshape the understanding of MS treatments.
Oct 16, 2023
0
51
Combining a PD-1 immune checkpoint inhibitor with standard chemotherapy improved quality of life for patients with advanced stomach cancer or esophageal cancer compared to chemotherapy alone, according to recent findings ...
Oct 12, 2023
0
45
Every winter, Canadian pediatric hospitals experience a wave of admissions linked to respiratory syncytial virus (RSV), one of the leading causes of hospitalization among children. These hospitalizations represent a major ...
Oct 4, 2023
0
33
Dozens of diabetes patients in Pakistan suffered vision loss after being given a contaminated drug, a provincial health official said Tuesday.
Sep 26, 2023
0
39
Pakistan's health minister said Sunday that an injectable medicine that was causing a severe eye infection and sight loss in diabetic patients in the province of Punjab has been recalled and an investigation ordered while ...
Sep 24, 2023
0
75
A combination immunotherapy treatment of nivolumab plus ipilimumab was associated with no improvement in survival for advanced cancers other than melanoma, when compared to nivolumab alone, according to a recent Northwestern ...
Sep 22, 2023
0
90
Tennessee last year spent $48 million on a single drug, Humira—about $62,000 for each of the 775 patients who were covered by its employee health insurance program and receiving the treatment. So when nine Humira knockoffs, ...
Sep 21, 2023
0
66
National medicine regulator, the Food and Drug Administration (FDA), recently approved the world's first vaccines to prevent RSV, or respiratory syncytial virus, for infants and elderly adults.
Sep 14, 2023
0
49
Researchers at Memorial Sloan Kettering Cancer Center, New York, have concluded their phase 2 trial of chemotherapy in combination with the drugs nivolumab, and regorafenib.
